Enhanced immunogenicity, mortality protection, and reduced viral brain invasion by alum adjuvant with an H5N1 split-virion vaccine in the Ferret

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Layton, Robert Colby ^a   Gigliotti, Andrew ^a   Armijo, Penny ^a   Myers, Leslie ^a   Knight, Jennifer ^a   Donart, Nathaniel ^a   Pyles, John ^a   Vaughan, Sarah ^a   Plourde, Jennifer ^a   Fomukong, Ndingsa ^a   Harrod, Kevin S ^a   Gao, Peng ^a   Koster, Frederick ^a  

^a LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; INFLUENZA VACCINE; SODIUM CHLORIDE; VIRUS ANTIBODY; IMMUNOLOGICAL ADJUVANT; VIRUS VACCINE;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CYTOPENIA; FEVER; HEMAGGLUTINATION INHIBITION; HISTOPATHOLOGY; IMMUNOGENICITY; INFLUENZA A (H5N1); INFLUENZA VIRUS A H5N1; MORTALITY; NONHUMAN; SURVIVAL RATE; SURVIVOR; THROMBOCYTOPENIA; VIRION; VIRUS ENCEPHALITIS; VIRUS LOAD; VIRUS NEUTRALIZATION; VIRUS STRAIN; WEIGHT REDUCTION; ANIMAL; ANTIBODY PRODUCTION; BLOOD EXAMINATION; BRAIN; DRUG EFFECT; FERRET; IMMUNOLOGY; PHYSIOLOGY; SURVIVAL; TIME; VACCINATION; VIROLOGY;

ANIMALIA; AVES; MUSTELA;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIBODY FORMATION; BRAIN; FERRETS; HEMATOLOGIC TESTS; INFLUENZA A VIRUS, H5N1 SUBTYPE; SURVIVAL ANALYSIS; TIME FACTORS; VACCINATION; VIRAL LOAD; VIRAL VACCINES; VIRION;

EID: 79958109321     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020641     Document Type: Article

References (60)

1. Lebarbenchon C, Feare CJ, Renaud F, Thomas F, Gauthier-Clerc M, (2010) Persistence of highly pathogenic avian influenza viruses in natural ecosystems. Emerg Infect Dis 16: 1057-1062.
2. Hampson AW, (2006) Ferrets and the challenges of H5N1 vaccine formulation. J Infect Dis 194: 143-145.
3. Stephenson I, Gust I, Kieny MP, Pervikov Y, (2006) Development and evaluation of influenza pandemic vaccines. Lancet Infect Dis 6: 71-72.
4. Subbarao K, Joseph T, (2007) Scientific barriers to developing vaccines against avian influenza viruses. Nat Rev Immunol 7: 267-278.
5. Saville M, Marsh G, Hoffenbach A, (2008) Improving seasonal and pandemic influenza vaccines. Influenza Other Respi Viruses 2: 229-235.
6. Palache B, (2008) New vaccine approaches for seasonal and pandemic influenza. Vaccine 26: 6232-6236.
7. Riley S, Wu JT, Leung GM, (2007) Optimizing the Dose of Pre-Pandemic Influenza Vaccines to Reduce the Infection Attack Rate. PLoS Med 4: e218.
8. Gerhard W, (2001) The role of the antibody response in influenza virus infection. Curr Top Microbiol Immunol 260: 171-190.
9. Hoffmann E, Lipatov AS, Webby RJ, Govorkova EA, Webster RG, (2005) Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N1 influenza virus vaccines. Proc Natl Acad Sci U S A 102: 12915-12920.
10. Baras B, Stittelaar KJ, Simon JH, Thoolen RJMM, Mossman SP, et al. (2008) Cross-Protection against Lethal H5N1 Challenge in Ferrets with an Adjuvanted Pandemic Influenza Vaccine. PLoS ONE 3: e1401.
11. Middleton D, Rockman S, Pearse M, Barr I, Lowther S, et al. (2009) Evaluation of vaccines for H5N1 influenza virus in ferrets reveals the potential for protective single-shot immunization. J Virol 83: 7770-7778.
12. Ruat C, Caillet C, Bidaut A, Simon J, Osterhaus AD, (2008) Vaccination of macaques with adjuvanted formalin-inactivated influenza A virus (H5N1) vaccines: protection against H5N1 challenge without disease enhancement. J Virol 82: 2565-2569.
13. Treanor JJ, Schiff GM, Hayden FG, Brady RC, Hay CM, et al. (2007) Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. Jama 297: 1577-1582.
14. Chotpitayasunondh T, Thisyakorn U, Pancharoen C, Pepin S, Nougarede N, (2008) Safety, humoral and cell mediated immune responses to two formulations of an inactivated, split-virion influenza A/H5N1 vaccine in children. PLoS One 3: e4028.
15. Zangwill KM, Treanor JJ, Campbell JD, Noah DL, Ryea J, (2008) Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans. J Infect Dis 197: 580-583.
16. Govorkova EA, Webby RJ, Humberd J, Seiler JP, Webster RG, (2006) Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J Infect Dis 194: 159-167.
17. Nolan T, Richmond PC, Formica NT, Hoschler K, Skeljo MV, et al. (2008) Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Vaccine 26: 6383-6391.
18. Szretter KJ, Balish AL, Katz JM, (2006) Influenza: propagation, quantification, and storage. Curr Protoc Microbiol Chapter 15 Unit 15G 11.
19. Harmon MW, Rota PA, Walls HH, Kendal AP, (1988) Antibody response in humans to influenza virus type B host-cell-derived variants after vaccination with standard (egg-derived) vaccine or natural infection. J Clin Microbiol 26: 333-337.
20. Rowe T, Abernathy RA, Hu-Primmer J, Thompson WW, Lu X, et al. (1999) Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 37: 937-943.
21. Kayali G, Setterquist SF, Capuano AW, Myers KP, Gill JS, et al. (2008) Testing human sera for antibodies against avian influenza viruses: horse RBC hemagglutination inhibition vs. microneutralization assays. J Clin Virol 43: 73-78.
22. Maher JA, DeStefano J, (2004) The ferret: an animal model to study influenza virus. Lab Anim (NY) 33: 50-53.
23. Pearson RC, Gorham JR, (1998) Viral Disease Models. In: Fox JG, editors. Biology and Diseases of the Ferret. 2nd ed Baltimore, MD Lippincott Williams & Wilkins pp. 487-498.
24. Tripp RA, Tompkins SM, (2009) Animal models for evaluation of influenza vaccines. Curr Top Microbiol Immunol 333: 397-412.
25. Belser JA, Szretter KJ, Katz JM, Tumpey TM, (2009) Use of animal models to understand the pandemic potential of highly pathogenic avian influenza viruses. Adv Virus Res 73: 55-97.
26. Maines TR, Chen LM, Matsuoka Y, Chen H, Rowe T, et al. (2006) Lack of transmission of H5N1 avian-human reassortant influenza viruses in a ferret model. Proc Natl Acad Sci U S A 103: 12121-12126.
27. van Riel D, Munster VJ, de Wit E, Rimmelzwaan GF, Fouchier RA, et al. (2007) Human and avian influenza viruses target different cells in the lower respiratory tract of humans and other mammals. Am J Pathol 171: 1215-1223.
28. Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD, (2004) Human and avian influenza viruses target different cell types in cultures of human airway epithelium. Proc Natl Acad Sci U S A 101: 4620-4624.
29. Zitzow LA, Rowe T, Morken T, Shieh WJ, Zaki S, et al. (2002) Pathogenesis of avian influenza A (H5N1) viruses in ferrets. J Virol 76: 4420-4429.
30. Maines TR, Lu XH, Erb SM, Edwards L, Guarner J, et al. (2005) Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals. J Virol 79: 11788-11800.
31. Layton RC, Armijo P, Myers L, Knight J, Donart N, et al. (2009) Ferret model of avian influenza demonstrates dose and strain dependant pathology and viral load in brain. Procedia in Vaccinology 1: 30-34.
32. Price GE, Soboleski MR, Lo C-Y, Misplon JA, Pappas C, et al. (2009) Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Vaccine 27: 6512-6521.
33. Salomon R, Franks J, Govorkova EA, Ilyushina NA, Yen HL, et al. (2006) The polymerase complex genes contribute to the high virulence of the human H5N1 influenza virus isolate A/Vietnam/1203/04. J Exp Med 203: 689-697.
34. Nicholson KG, Colegate AE, Podda A, Stephenson I, Wood J, et al. (2001) Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357: 1937-1943.
35. Leroux-Roels I, Borkowski A, Vanwolleghem T, Drame M, Clement F, et al. (2007) Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370: 580-589.
36. Lipatov AS, Hoffmann E, Salomon R, Yen HL, Webster RG, (2006) Cross-protectiveness and immunogenicity of influenza A/Duck/Singapore/3/97(H5) vaccines against infection with A/Vietnam/1203/04(H5N1) virus in ferrets. J Infect Dis 194: 1040-1043.
37. Tripp RA, Tompkins SM, (2008) Recombinant vaccines for influenza virus. Curr Opin Investig Drugs 9: 836-845.
38. Atmar RL, Keitel WA, (2009) Adjuvants for pandemic influenza vaccines. Curr Top Microbiol Immunol 333: 323-344.
39. Fang Y, Rowe T, Leon AJ, Banner D, Danesh A, et al. (2010) Molecular characterization of in vivo adjuvant activity in ferrets vaccinated against influenza virus. J Virol 84: 8369-8388.
40. Bresson JL, Perronne C, Launay O, Gerdil C, Saville M, et al. (2006) Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367: 1657-1664.
41. Keitel WA, Campbell JD, Treanor JJ, Walter EB, Patel SM, et al. (2008) Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. J Infect Dis 198: 1309-1316.
42. Brady RC, Treanor JJ, Atmar RL, Keitel WA, Edelman R, et al. (2009) Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults. Vaccine 27: 5091-5095.
43. Bernstein DI, Edwards KM, Dekker CL, Belshe R, Talbot HK, et al. (2008) Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 197: 667-675.
44. Epstein SL, (2006) Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature. J Infect Dis 193: 49-53.
45. Garcia JM, Pepin S, Lagarde N, Ma ES, Vogel FR, et al. (2009) Heterosubtype neutralizing responses to influenza A (H5N1) viruses are mediated by antibodies to virus haemagglutinin. PLoS One 4: e7918.
46. Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, et al. (2009) In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460: 1021-1025.
47. Grebe KM, Yewdell JW, Bennink JR, (2008) Heterosubtypic immunity to influenza A virus: where do we stand? Microbes Infect 10: 1024-1029.
48. Throsby M, van den Brink E, Jongeneelen M, Poon LL, Alard P, et al. (2008) Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 3: e3942.
49. Sui J, Hwang WC, Perez S, Wei G, Aird D, et al. (2009) Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16: 265-273.
50. Sandbulte MR, Jimenez GS, Boon AC, Smith LR, Treanor JJ, et al. (2007) Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med 4: e59.
51. Yetter RA, Barber WH, Small PA Jr, (1980) Heterotypic immunity to influenza in ferrets. Infect Immun 29: 650-653.
52. Govorkova EA, Rehg JE, Krauss S, Yen HL, Guan Y, et al. (2006) Lethality to Ferrets of H5N1 Influenza Viruses Isolated from Humans and Poultry in 2004; Author's correction. J Virol 80: 6195.
53. Webby RJ, Andreansky S, Stambas J, Rehg JE, Webster RG, et al. (2003) Protection and compensation in the influenza virus-specific CD8+ T cell response. Proc Natl Acad Sci U S A 100: 7235-7240.
54. Co MD, Orphin L, Cruz J, Pazoles P, Rothman AL, et al. (2008) Discordance between antibody and T cell responses in recipients of trivalent inactivated influenza vaccine. Vaccine 26: 1990-1998.
55. Gillim-Ross L, Subbarao K, (2007) Can immunity induced by the human influenza virus N1 neuraminidase provide some protection from avian influenza H5N1 viruses? PLoS Med 4: e91.
56. Miao H, Hollenbaugh JA, Zand MS, Holden-Wiltse J, Mosmann TR, et al. (2010) Quantifying the early immune response and adaptive immune response kinetics in mice infected with influenza A virus. J Virol 84: 6687-6698.
57. Shinya K, Makino A, Hatta M, Watanabe S, Kim JH, et al. (2011) Subclinical brain injury caused by H5N1 influenza virus infection. J Virol March 9 [Epub ahead of print].
58. Rowe T, Cho DS, Bright RA, Zitzow LA, Katz JM, (2003) Neurological manifestations of avian influenza viruses in mammals. Avian Dis 47: 1122-1126.
59. Jang H, Boltz D, Sturm-Ramirez K, Shepherd KR, Jiao Y, et al. (2009) Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration. Proc Nat Acad Sci US 106: 14063-14068.
60. Mori I, Kimura Y, (2001) Neuropathogenesis of influenza virus infection in mice. Microbes Infect 3: 475-479.